Herceptin Market to Grow with a CAGR of 5.77% through 2030
Advancements in
oncology drug development, and growing awareness regarding personalized cancer
treatment, is expected to drive the Global Herceptin Market growth in the
forecast period, 2026-2030
According to
TechSci Research report, “Herceptin Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030F”, the Global Herceptin
Market stood at USD 3.51
Billion in 2024 and is expected to reach USD 4.92 Billion by
2030 with a CAGR of 5.77% during the forecast period. The Global Herceptin Market is evolving
with significant transformation across cancer therapeutics, supported by a
deeper understanding of oncogenic pathways and tumor biology. Herceptin, a
targeted therapy against the HER2 receptor, has become a benchmark in the
treatment of HER2-overexpressing cancers. Enhanced clinical guidelines from
oncology associations and continuous improvements in patient screening programs
have led to more accurate identification of candidates suitable for
trastuzumab-based therapies. With expanding patient pools undergoing HER2
testing, the demand for targeted biologics is accelerating. Pharmaceutical
partnerships and hospital collaborations are also enhancing the delivery and
accessibility of Herceptin across varied healthcare systems, reinforcing its
role in modern oncology.
Technological
advancement is playing a pivotal role in reshaping the Herceptin landscape. The
use of real-world evidence and big data analytics is being incorporated into
treatment planning, allowing clinicians to monitor therapy outcomes and adapt
protocols for maximum efficacy. Digital health platforms and e-health records
are streamlining cancer care management, supporting better compliance with
complex treatment schedules. The market is also influenced by the increasing
preference for outpatient and home-based cancer therapies, where trastuzumab's
newer formulations are well-suited. In parallel, pharmaceutical companies are
investing in patient assistance programs and education campaigns to ensure
better adherence and awareness about biologic therapies.
The
Global Herceptin Market holds untapped potential across various therapeutic
domains and geographies. There is growing research exploring trastuzumab’s
efficacy in combination with immune checkpoint inhibitors, which could broaden
its clinical utility. Expanding focus on rare and less common HER2-expressing
cancers such as uterine serous carcinoma or certain colorectal cancers presents
a new horizon for the drug's application. Strategic entry of biosimilars is not
only intensifying competition but also encouraging innovation around improved
delivery mechanisms, including auto-injectors and long-acting injectables. As
healthcare infrastructure improves in emerging markets, there is greater
opportunity for Herceptin-based therapies to gain traction through
government-sponsored oncology programs, creating pathways for wider global
uptake and therapeutic impact.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Herceptin Market”
The Global Herceptin
Market is segmented into product, application, distribution channel, regional
distribution, and company.
Based on the Application,
Stomach/Gastric Cancer emerged as the fastest growing segment in the Global Herceptin
Market during the forecast period. This is due to the increasing global incidence of HER2-positive
gastric and gastroesophageal junction (GEJ) cancers, along with evolving
treatment protocols that incorporate trastuzumab as a standard first-line
therapy. Traditionally, Herceptin has been widely used in breast cancer;
however, its proven efficacy in targeting HER2 overexpression in gastric cancer
has driven its clinical adoption in this area. Clinical trials such as the ToGA
(Trastuzumab for Gastric Cancer) study provided pivotal evidence supporting the
use of trastuzumab in combination with chemotherapy, significantly improving
survival outcomes in patients with HER2-positive metastatic gastric cancer.
Regulatory approvals in key markets for this indication have expanded the scope
of Herceptin's therapeutic use, encouraging oncologists to adopt it more widely
for gastric cancer patients.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Herceptin Market during the
forecast period. This is due to the entry and rapid expansion of biosimilar
versions of Herceptin. Local biopharmaceutical companies and global biosimilar
developers have capitalized on favorable regulatory environments and lower
production costs to introduce cost-effective trastuzumab alternatives, widening
access among middle-income populations. Countries like India and China have
become hubs for biosimilar manufacturing, supported by strong R&D
capabilities and large domestic markets. This has resulted in competitive
pricing and increased market penetration, particularly in regions where
affordability has historically limited access to originator biologics.
Regulatory authorities such as the National Medical Products Administration
(NMPA) in China and the Central Drugs Standard Control Organization (CDSCO) in
India have streamlined biosimilar approval pathways, encouraging new product
launches. Moreover, increasing clinical research activities in Asia-Pacific,
including local trials for trastuzumab combinations and new indications, are attracting
investment and strengthening the region’s role in global oncology treatment
innovation.
Major
companies operating in Global Herceptin Market are:
- Roche
Holding AG
- Pfizer
Inc.
- Samsung
Bioepis Co., Ltd.
- Amgen
Inc.
- Celltrion
Healthcare Co., Ltd.
- Biocon
Limited
- Mylan
N.V. (Viatris)
- Prestige
Biopharma
- Shanghai
Henlius Biotech, Inc.
- Dr.
Reddy’s Laboratories
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Global Herceptin Market is expanding
due to the rising investment in HER2-focused clinical research aimed at
exploring new indications and combination therapies involving trastuzumab.
Pharmaceutical companies and academic institutions are actively conducting
trials to assess Herceptin’s efficacy in early-stage cancers, brain metastases,
and in synergy with novel immunotherapies. This growing research pipeline not
only supports label expansion but also strengthens the clinical relevance of
Herceptin across a wider spectrum of oncology applications. The momentum in
R&D is contributing to extended usage, increased prescriptions, and longer
treatment durations, reinforcing Herceptin’s position as a foundational therapy
in HER2-positive cancer care.,” said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“Herceptin Market -
Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By
Product (Biologic, Biosimilar), By Application (Breast Cancer, Stomach/Gastric
Cancer, Others), By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy,
Others), By Region and Competition, 2020-2030F”, has evaluated
the future growth potential of Global Herceptin Market and provides statistics
& information on market size, structure and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Herceptin Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com